Alert: Federal Executive Order Signed to Fast-Track Psychedelic Research & FDA Approval

U.S. President Donald Trump has signed an executive order titled 'Accelerating Medical Treatments for Serious Mental Illness,' directing federal agencies to streamline FDA approval for 'breakthrough' psychedelic medicines. This order prioritizes ibogaine research for veterans' mental health and substance use, backed by a $50 million federal initiative. Merchants in the psychedelic space should monitor developments as this signifies a major federal push to accelerate access and potentially reduce future regulatory barriers.

On April 18, U.S. President Donald Trump signed an executive order aimed at accelerating clinical research and federal approval for psychedelic therapies. The order, formally titled “Accelerating Medical Treatments for Serious Mental Illness,” directs federal agencies, including the Department of Health and Human Services (HHS) and the Department of Veterans Affairs (VA), to reduce regulatory barriers and streamline the Food and Drug Administration (FDA) approval pathway for “breakthrough” psychedelic medicines. Ibogaine has been highlighted as a priority for treating veteran mental health and substance use disorders, with President Trump also announcing a $50 million federal initiative to study the substance.

Sentinel Insight